What is the share price of Inventurus Knowledge Solutions Ltd (IKS) today?
The share price of IKS as on 5th May 2026 is ₹1686.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Inventurus Knowledge Solutions Ltd (IKS) share?
The past returns of Inventurus Knowledge Solutions Ltd (IKS) share are- Past 1 week: 11.20%
- Past 1 month: 25.59%
- Past 3 months: -1.00%
- Past 6 months: 1.15%
- Past 1 year: 14.17%
- Past 3 years: N/A%
- Past 5 years: -13.99%
What are the peers or stocks similar to Inventurus Knowledge Solutions Ltd (IKS)?
The peers or stocks similar to Inventurus Knowledge Solutions Ltd (IKS) include:What is the market cap of Inventurus Knowledge Solutions Ltd (IKS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Inventurus Knowledge Solutions Ltd (IKS) is ₹28137.93 Cr as of 5th May 2026.What is the 52 week high and low of Inventurus Knowledge Solutions Ltd (IKS) share?
The 52-week high of Inventurus Knowledge Solutions Ltd (IKS) is ₹1876 and the 52-week low is ₹1262.What is the PE and PB ratio of Inventurus Knowledge Solutions Ltd (IKS) stock?
The P/E (price-to-earnings) ratio of Inventurus Knowledge Solutions Ltd (IKS) is 57.89. The P/B (price-to-book) ratio is 15.72.Which sector does Inventurus Knowledge Solutions Ltd (IKS) belong to?
Inventurus Knowledge Solutions Ltd (IKS) belongs to the Health Care sector & Health Care Equipment & Supplies sub-sector.How to buy Inventurus Knowledge Solutions Ltd (IKS) shares?
You can directly buy Inventurus Knowledge Solutions Ltd (IKS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Inventurus Knowledge Solutions Ltd
IKS Share Price
NSEIKS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is underpriced but is in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
IKS Performance & Key Metrics
IKS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 42.42 | 15.72 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.37 | 6.00 | 0.56% |
from 8 analysts
Price Upside
Earnings Growth
Rev. Growth
IKS Company Profile
Inventurus Knowledge Solutions Limited provides technology-enabled healthcare solutions, focusing on outpatient and inpatient care through its comprehensive care enablement platform.
IKS Sentiment Analysis
IKS Sentiment Analysis
IKS Stock Summary · February 2026
The company has demonstrated robust financial performance, achieving a 24% year-on-year revenue growth and a 40.4% increase in EBITDA, driven by a strategic shift towards an AI-first model that enhances operational efficiency. Despite the promising growth trajectory, challenges persist, particularly in client integration and adapting to complex electronic health record systems, which can hinder market share capture. The outcome-based revenue model aligns the company's success with that of its clients, although declining reimbursement rates pose risks to margins. As the competitive landscape evolves, the company is focused on solidifying its position in both small and large health systems, leveraging strategic partnerships and innovative technologies to navigate market uncertainties and drive future growth.
IKS Stock Growth Drivers
IKS Stock Growth Drivers
7Strong Financial Performance
The company has reported significant financial achievements, including a 24% year-on-year revenue growth for the
Effective Use of Technology
The company has successfully transitioned to a tech-led, AI-first approach, leveraging technology to decouple revenue
IKS Stock Challenges
IKS Stock Challenges
4Financial Adjustments and One-off Items
The company has faced tangible financial setbacks due to one-off items affecting its financial results.
Market Unpredictability and Revenue Guidance
The company acknowledges the unpredictability of the market, which has led to a lack of
IKS Forecast
IKS Forecasts
Price
Revenue
Earnings
IKS Share Price Forecast
IKS Share Price Forecast
All values in ₹
All values in ₹
IKS Company Revenue Forecast
IKS Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
IKS Stock EPS (Earnings Per Share) Forecast
IKS Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
IKS
IKS
Income
Balance Sheet
Cash Flow
IKS Income Statement
IKS Income Statement
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 573.05 | 634.59 | 643.67 | 647.95 | 684.15 | 727.22 | 743.21 | 784.75 | 820.50 | |||||||||
| Operating & Other expenses | 404.83 | 494.15 | 467.11 | 453.70 | 475.70 | 497.78 | 502.34 | 510.75 | 535.74 | |||||||||
| EBITDA | 168.22 | 140.44 | 176.56 | 194.25 | 208.45 | 229.44 | 240.87 | 274.00 | 284.76 | |||||||||
| Depreciation/Amortization | 18.98 | 27.38 | 28.25 | 28.33 | 27.76 | 28.33 | 27.90 | 30.14 | 32.05 | |||||||||
| PBIT | 149.24 | 113.06 | 148.31 | 165.92 | 180.69 | 201.11 | 212.97 | 243.86 | 252.71 | |||||||||
| Interest & Other Items | 25.56 | 32.20 | 25.98 | 22.23 | 20.54 | 21.02 | 18.08 | 16.15 | 23.34 | |||||||||
| PBT | 123.68 | 80.86 | 122.33 | 143.69 | 160.15 | 180.09 | 194.89 | 227.71 | 229.37 | |||||||||
| Taxes & Other Items | 22.15 | 17.30 | 26.86 | 30.70 | 30.48 | 32.29 | 43.34 | 46.99 | 46.05 | |||||||||
| Net Income | 101.53 | 63.56 | 95.47 | 112.99 | 129.67 | 147.80 | 151.55 | 180.72 | 183.32 | |||||||||
| EPS | 6.14 | 3.84 | 5.75 | 6.80 | 7.80 | 8.88 | 9.07 | 10.81 | 10.96 |
IKS Company Updates
Investor Presentation
IKS Stock Peers
IKS Past Performance & Peer Comparison
IKS Past Performance & Peer Comparison
Health CareHealth Care Equipment & Supplies
Valuation
Technical
Forecast
| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Inventurus Knowledge Solutions Ltd | 57.89 | 15.72 | — |
| Poly Medicure Ltd | 45.74 | 5.60 | 0.23% |
| Tarsons Products Ltd | 39.96 | 1.89 | — |
| Laxmi Dental Ltd | 36.31 | 5.53 | — |
IKS Stock Price Comparison
Compare IKS with any stock or ETFIKS Holdings
IKS Shareholdings
IKS Promoter Holdings Trend
IKS Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
IKS Institutional Holdings Trend
IKS Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
IKS Shareholding Pattern
IKS Shareholding Pattern
IKS Shareholding History
IKS Shareholding History
Mutual Funds Invested in IKS
Mutual Funds Invested in IKS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Inventurus Knowledge Solutions Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4011% | Percentage of the fund’s portfolio invested in the stock 0.47% | Change in the portfolio weight of the stock over the last 3 months -0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 97/150 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2848% | Percentage of the fund’s portfolio invested in the stock 0.46% | Change in the portfolio weight of the stock over the last 3 months 0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 137/157 (+5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2130% | Percentage of the fund’s portfolio invested in the stock 0.48% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 44/79 (+6) |
Compare 3-month MF holding change on Screener
smallcases containing IKS stock
smallcases containing IKS stock
Looks like this stock is not in any smallcase yet.
IKS Events
IKS Events
IKS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
IKS Dividend Trend
No dividend trend available
IKS Dividends
IKS Dividends
IKS Stock News & Opinions
IKS Stock News & Opinions
TruBridge is a fully integrated clinical and financial partner for small and mid-small size hospitals in the USA, offering electronic medical records (EMR) solutions and revenue cycle management (RCM) services. This proposed strategic acquisition underscores a commitment to broaden access to high-quality care and support the clinicians and hospitals that serve communities across the United States. The combined company would bring together IKS Health's care enablement services and TruBridge's expertise in revenue cycle management and electronic health record solutions, particularly for rural and community hospitals. Its goal is to strengthen local healthcare systems and improve access to essential care closer to patients' homes while supporting both ambulatory and acute care. After the merger, the company will focus on improving workflows and operations by combining artificial intelligence with human oversight to address complex challenges. As it integrates more clinical and financial data, the platform is expected to become more efficient and effective, helping healthcare organizations maintain financial stability and focus on patient care. Overall, the organization will provide revenue cycle management, predictive analytics, and advanced EHR solutions to over 2,000 healthcare organizations and more than 150,000 clinicians to improve clinical, operational, and financial performance. Under the terms of the agreement, TruBridge shareholders will receive $26.25 in cash for each share of common stock. The acquisition has been approved by the Boards of Directors of IKS Health, IKS, and TruBridge, and is expected to close during the third calendar quarter of 2026, subject to the satisfaction of customary closing conditions. IKS will finance the acquisition primarily through the incurrence of new indebtedness, including a term loan underwritten by Citibank, JPMorganChase, and Deutsche Bank, which is subject to satisfaction of customary conditions (including approval of the shareholders of IKS Health). Inventurus Knowledge Solutions (IKS Health) is a leading technology enabled healthcare solutions provider, primarily serving the US healthcare market. It offers a comprehensive care enablement platform that supports healthcare enterprises across outpatient and inpatient care settings. The company's consolidated net profit jumped 41.37% to Rs 183.32 crore on 24.01% jump in revenue from operations to Rs 814.95 crore in Q3 FY26 over Q3 FY25.
Inventurus Knowledge Solutions, Inc. (IKS), the U.S. subsidiary of Inventurus Knowledge Solutions (IKS Health), announced it has entered into a definitive agreement to acquire TruBridge, Inc. (NASDAQ: TBRG) (TruBridge), a prominent provider of healthcare technology solutions for rural and community hospitals. This proposed strategic acquisition underscores a commitment to broaden access to high-quality care and support the clinicians and hospitals that serve communities across the United States. By bringing together IKS Health's comprehensive care enablement capabilities that serve a range of healthcare organizations with TruBridge's deep expertise in supporting rural and community hospitals through revenue cycle management and electronic health record (EHR) solutions, the combined healthcare technology company is expected to strengthen local healthcare systems, and enable patients to receive essential care closer to home while also enhancing care delivery across the ambulatory and acute care continuum. Post closing, the combined company will deliver continuous improvement and connected workflows to the core of rural healthcare and to medical groups overall, combining agentic artificial intelligence (AI) with human-in-the-loop expertise to proactively address complex operational challenges. As the platform incorporates a broader range of clinical and financial data, it is designed to become increasingly intelligent and efficient. This growing intelligence, reinforced by human insight, is anticipated to ensure community hospitals and medical groups have the financial resilience and advanced support needed to focus on the health of their patients.
Inventurus Knowledge Solutions has approved grant of 75,000 employee stock options under the IKS ESOP Plan on 20 February 2026. Powered by Capital Market - Live
Profit before tax (PBT) climbed 43.22% YoY to Rs 229.37 crore in Q3 FY26. EBITDA jumped 40% to Rs 281.6 crore in Q3 FY26, registering the growth of 40% compared with Rs 271.8 crore in Q3 FY25.EBITDA margin improved to 34.6% in Q3 FY26 as against 30.5% in Q3 FY25. Sachin K. Gupta, founder & Global CEO, IKS Health,said, 'Our strong Q3 performance, characterized by 24% revenue growth, validatesthat our Care Enablement Platform is the critical solution for a US healthcare market facing a perfect storm of cost, quality, and access pressures. As physician marginsface renewed compression from stagnant reimbursement rates, we are seeing this act as a powerful catalyst for increased outsourcing and platform adoption. We continue to deepen our value proposition by advancing our AI capabilities'specifically moving our Patient Engagement suite toward multi-agent orchestration'to drive cognitive reasoning and independent action. Our recent wins with partners like StrideCare and VitalMD demonstrate that provider enterprises are increasingly choosing our integrated platform to ensure their financial sustainability and clinical efficiency.' Nithya Balasubramanian, Group CFO, IKS Health said, 'Our Q3 FY2026 performance underscores our consistent ability to drive profitable growth and deliver significant value to our clients. We achieved a 24% year-on-year revenue increase and a 41% growth in Profit After Tax (PAT), fueled by continuous expansion across existing and new client relationships. Margin expansion is a direct result of our successful operating leverage, technology deployment and focused cost management. ' Inventurus Knowledge Solutions (IKS Health) is a leading technology enabled healthcare solutions provider, primarily serving the US healthcare market. It offers a comprehensive care enablement platform that supports healthcare enterprises across outpatient and inpatient care settings.Powered by Capital Market - Live
Net profit of Inventurus Knowledge Solutions rose 41.37% to Rs 183.33 crore in the quarter ended December 2025 as against Rs 129.68 crore during the previous quarter ended December 2024. Sales rose 24.01% to Rs 814.95 crore in the quarter ended December 2025 as against Rs 657.16 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales814.95657.16 24 OPM %34.2627.61 - PBDT261.42187.91 39 PBT229.37160.16 43 NP183.33129.68 41 Powered by Capital Market - Live
Inventurus Knowledge Solutions will hold a meeting of the Board of Directors of the Company on 4 February 2026.Powered by Capital Market - Live
Inventurus Knowledge Solutions has allotted 4,70,000 equity shares under the IKS ESOP Plan on 04 December 2025.Powered by Capital Market - Live
Inventurus Knowledge Solutions announced the inauguration of its new office in Coimbatore today. The 1000-seat, state-of-the-art facility is designed to accommodate the rapid expansion of IKS Health's operations for the US Healthcare market. This new office is slated to become a significant talent hub, generating employment for recent university graduates, as well as experienced professionals with backgrounds in medicine, pharmacy, technology, and engineering. Nithya Balasubramanian, Whole-time Director & CFO, IKS Health said, 'Our second quarter performance for Fiscal Year 2026 demonstrates our commitment to consistent, profitable growth, evidenced by a 22% year-over-year growth in revenue, and a 60% rise in Profit After Tax (PAT). This sustained momentum is fundamentally driven by our talented workforce. The strategic expansion of our local talent base in Coimbatore is crucial, as it enhances our capacity for execution excellence and allows us to vigorously pursue our long-term objectives of enabling better, safer healthcare in the US market.' Powered by Capital Market - Live
Profit before tax (PBT) climbed 58.5% YoY to Rs 227.71 crore in Q2 FY26. EBITDA stood at Rs 271.8 crore, up 43% compared with Rs 189.8 crore posted in corresponding quarter last year. EBITDA margin improved to 34.8% in Q2 FY26 as against 29.5% in Q2 FY25. Sachin K. Gupta, Founder & Global CEO, IKS Health, said, 'The second quarter was a period of significant strategic execution and strong financial performance for IKS Health. Our results underscore the growing market demand for our Care Enablement Platform as health systems increasingly recognize the need to holistically address administrative, clinical, and financial challenges. A key highlight of this quarter was the launch of our Agentic AI platform on Google Cloud and native integration of Scribble Now, our ambient AI scribing solution, into revenue cycle management, coding, and clinical documentation workflows, creating the industry's first connected encounter-to-reimbursement platform and winning the 2025 Dora Award from Google Cloud Award for 'Augmenting Human Expertise with AI'. We have also significantly accelerated the execution of our AI strategy, marked by the appointment of our new Chief AI Officer. These accomplishments reflect our unwavering commitment to augmenting human expertise to deliver unparalleled clinical, financial, and operational excellence to our clients. Nithya Balasubramanian, Group CFO, IKS Health said, 'IKS Health's strong Q2 FY26 financial performance, highlighted by a 22% year-over-year Revenue, 43% EBITDA and 60% PAT growth reflects our continued focus on driving consistent, profitable growth. The improvement in our EBITDA margin showcases the scalability of our platform and disciplined capital management. ' Inventurus Knowledge Solutions (IKS Health) is a leading technology enabled healthcare solutions provider, primarily serving the US healthcare market. It offers a comprehensive care enablement platform that supports healthcare enterprises across outpatient and inpatient care settings.Powered by Capital Market - Live
Net profit of Inventurus Knowledge Solutions rose 59.93% to Rs 180.72 crore in the quarter ended September 2025 as against Rs 113.00 crore during the previous quarter ended September 2024. Sales rose 21.52% to Rs 781.09 crore in the quarter ended September 2025 as against Rs 642.78 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales781.09642.78 22 OPM %34.6129.42 - PBDT257.85172.03 50 PBT227.71143.70 58 NP180.72113.00 60 Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 37.02%, vs industry avg of 24.67%
Over the last 5 years, market share increased from 22.57% to 31.71%
Over the last 5 years, net income has grown at a yearly rate of 28.73%, vs industry avg of 30.01%